Clinical trials: Psoriasis Vulgaris
Psoriasis Vulgaris
A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.
- Trial name
- NCT01116895
- Testing
- LEO 22811
- Where
- 2 sites in Canada, France
- Volunteers
- 63 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment
Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08 during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled with current therapy.
- Trial name
- NCT02796053
- Testing
- TAB08
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Theramab LLC
Plaque Psoriasis, Psoriasis Vulgaris
Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis
The purpose of this study is to determine whether using Taclonex ointment under a hydrogel patch is more effective than using the ointment alone in treating psoriasis.
- Trial name
- NCT00924950
- Testing
- Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Psoriasis Vulgaris
Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris
The purpose of this observational study is to evaluate the efficacy, tolerability, quality of life and handling of Daivobet® Gel by both physician and patient in daily practise.
- Trial name
- NCT01320774
- Testing
- Daivobet® Gel
- Where
- Germany
- Volunteers
- 588 people
- Sponsor
- LEO Pharma
Psoriasis, Psoriasis Vulgaris
Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris
The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression of a variety of cytokines and adhesion molecules. Recently much attention has focused on the Junctional Adhesion Molecules (JAM).
- Trial name
- NCT00365625
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Psoriasis Vulgaris
A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects
The purpose of this study is to investigate the effects of multiple oral doses of LEO 32731 on the pharmacokinetics of a single oral dose of the cytochrome P450 3A substrate midazolam in healthy male subjects.
- Trial name
- NCT02753218
- Testing
- Midazolam, LEO 32731
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Psoriasis Vulgaris, UVB Phototherapy Burn
Effect Narrow-Band UVB Radiations
Narrow-band UVR affects Interleukin 17 which has a major role in the pathogenesis of psoriasis Vulgaris. the aim of this study to evaluate the serum levels of Interleukin 17 in psoriatic patients and compare with the levels in…
- Trial name
- UVB (NCT05647187)
- Testing
- Serum Interleukin 17 levels, NB-UVB
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- South Valley University
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriasis Vulgaris
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
The main objective of this study is to investigate whether controlled dose reduction of IL17 or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients.
- Trial name
- BeNeBio (NCT04340076)
- Testing
- Secukinumab, Ixekizumab, Brodalumab
- Where
- 19 sites in Belgium, Netherlands
- Volunteers
- 244 people
- Sponsor
- Radboud University Medical Center
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body.
- Trial name
- NCT00691002
- Testing
- Calcipotriol plus hydrocortisone (LEO 80190), LEO 80190 Vehicle, Hydrocortisone
- Where
- 11 sites in Croatia, Germany and 2 more
- Volunteers
- 1,245 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Laser Induced Changes to Innervation and Vascularisation of Psoriatic Skin
The researchers investigate the effect of a treatment with selective photothermolysis using a 595 nm pulsed dye laser on the blood vessel density and the nerve fibre density of a psoriatic lesion.
- Trial name
- LPA-01 (NCT05079256)
- Testing
- 595 nm Pulsed dye laser (Candela V-beam perfecta)
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- Nick van der Beek
Psoriasis Vulgaris
An Explorative Psoriasis Biomarker Study
Plaque psoriasis may be an ideal model disease to explore potential therapeutic effects of immunosuppressive agents, given the easy accessibility of inflammatory lesions.
- Trial name
- NCT04394936
- Testing
- Guselkumab
- Where
- Netherlands
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Centre for Human Drug Research, Netherlands
Psoriasis Vulgaris
Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis
Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago has shown excellent efficacy in the…
- Trial name
- NCT03348462
- Testing
- ethosomal preparation of anthralin, liposomal preparation of anthralin
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris.
- Trial name
- NCT02899962
- Testing
- LEO 90100 aerosol foam, LEO 90100 aerosol foam vehicle
- Where
- 58 sites in United States, Canada and 4 more
- Volunteers
- 722 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with psoriasis vulgaris who failed at least one…
- Trial name
- NCT02317627
- Testing
- KD025
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Kadmon Corporation, LLC
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects
The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral…
- Trial name
- NCT00833872
- Testing
- LEO 22811
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriasis Vulgaris
Impact of the Mediterranean Diet on Patients with Psoriasis
The goal of this clinical trial is to determine the effect of a high-intensity Mediterranean diet intervention over 16 weeks in a group of patients with mild to moderate psoriasis in terms of skin improvement as measured by PASI.
- Conditions
- Psoriasis, Psoriasis Vulgaris, Hyperlipidemias, Depression
- Trial name
- MEDIPSO (NCT06257641)
- Testing
- High-intensity Mediterranean diet intervention
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Psoriasis Vulgaris
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
To assess safety, tolerability and pharmacodynamics effect of treatment with microarray patches containing calcipotriol and betamethasone dipropionate.
- Trial name
- NCT03898583
- Testing
- Microarray patch A, Microarray patch B, Daivobet
- Where
- 2 sites in Germany
- Volunteers
- 15 people
- Sponsor
- LEO Pharma